F. Hoffmann-La Roche Ltd, Siemens Healthcare Private Limited and BD are Dominating the Asia-Pacific Point-of-Care Testing (POCT) Market in 2019

Asia-Pacific Point-Of-Care Testing (POCT) Market is expected to grow with the CAGR of 10.2% in the forecast period of 2020 to 2027. The years considered for study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/apac-point-care-testing-poct-market

Point-of-care testing (POCT) market is a highly consolidated market, which includes specific number of key players as well as local players. The market has witnessed increased strategic developments owing to favourable market scenario.

The major players dealing in point-of-care testing (POCT) market are introducing strong range of product portfolio. This helped companies to maximize the sales with enhanced product portfolio.

For instance,

  • In May 2019, Backman Coulter, Inc. had introduced total laboratory automation solution that sets new standard for turnaround time. This automation solution services will help in getting good quality results and will improve laboratory operations. This will help the company in setting new standard of quality services and hence will help in generating more revenue in future.
  • In December 2017, Sekisui Diagnostics has announced to distribute the Mesa Biotech Point of care molecular system for Flu A/Flu B. It helps physicians with rapid infectious disease diagnosis at the point of care with increased sensitivity. Thus, this will help the company in more revenue generation

Asia-Pacific Point-of-Care Testing (POCT) Market

F. Hoffmann-La Roche Ltd

F. Hoffmann-La Roche Ltd headquartered in Basel, Switzerland, which was founded in 1896 as public owner ship. The company is engaged in creating innovative medicines and diagnostics tests that help millions of people worldwide. The company have business segment such as Pharmaceuticals, Diagnostics in which Diagnostics is the focused category. The company have wide product category such as Pharmaceuticals, Solutions for Diagnostics, Products for Researchers.

The company has wide global presence across the globe such as North America, Europe, Africa, Asia and Oceania. The company also generates its revenue from various subsidiaries such as Roche Diagnostica Brasil Ltda. (Brazil), Roche Diabetes Care Brasil Ltda. (Brazil), Trophos SA (France), INSTITUT ROCHE SAS (France) and Roche Diagnostics K.K. (Japan) among others.

 For instance,

  • In June 2014, F. Hoffmann-La Roche Ltd had launched a fully automated urine testing analyzer which can process more than one thousand urine samples per day. The major goal of the company is to focus on the development of digital examination in testing and to provide higher quality solutions to the laboratories. This launch helped the company to broaden its product portfolio of urinalysis.

Siemens Healthcare Private Limited

Siemens Healthcare Private Limited is headquartered in Erlangen, Germany and it was founded in year 1896 as private ownership. The company is engaged in the manufacturing and commercializing of laboratory diagnostics, medical imaging, digital ecosystem and reading solutions across the world. The company offers wide range of product categories such as Medical Imaging, Laboratory Diagnostics, Point of Care Testing, Digital Health Solutions, Services & Consulting, Clinical Specialties, Accessories, OEM & Electronics & Healthcare IT.

The company has presence in a North America, Europe, Asia-Pacific, South America, Middle East and Africa with its various subsidiaries such as Fast Track Diagnostics Ltd. (Europe), Siemens Healthcare Medical Solutions Limited (Germany) and Siemens Healthcare Germany (Germany) among others.

For instance,

  • In August 2020, Siemens Healthcare Private Limited has announced that they have agreed to the acquisition of the company named Varian to enhance the fight against cancer and for strengthening their business in the healthcare sector. It will help the company in the enhancement of its credibility in the market.     

BD

BD is headquartered in New Jersey, U.S. and founded in 1897 as public ownership. The company is engaged in manufacturing and commercializing of wide range of products such as direct testing products, environmental systems, prepared media products and others. The company have business segment such as Medical, Life Sciences and Interventional. The company has product category which are Anesthesia Delivery, Biopsy, Biosciences, Biosurgery, Cervical Cancer Screening, Diabetes Care, Drug Delivery Systems, Drainage, Gastrointestinal Care, Hazardous Drug Safety, Hernia Repair and Fixation, Home Care, Infection Prevention, Infusion Therapy, Interventional Specialties, Lab Automation, Medication and Supply Management, Microbiology Solutions, Molecular Diagnostics, Patient Monitoring and Temperature Management, Prostate Health, Respiratory Care, Sharps Disposal Solutions, Software Solutions, Specimen Collection, Surgical Instruments, Syringes and Needles, Urology and Kidney Health, Vascular Access, Wound Care.

The company has wide global presence in North America, South America, Europe, Asia-Pacific, Middle East and Africa. Accuri Cytometers, Inc. (Delaware), Accuri Cytometers (Europe), Ltd. (U.K.), Atto Bioscience, Inc. (Delaware), B-D (Cambridge U.K.) Ltd. (U.K.) among others.

For instance,

  • In July 2020, BD had launched a point-of-care SARS-CoV-2 diagnostic test named as BD Veritor Plus System. This is a rapid and new assay that can deliver results within 15 minutes and is a highly portable instrument that is useful for improving access to COVID-19 diagnosis. This new product launch has diversified the company product portfolios.